Please type a plus sign (+) inside this box ____

JUN 2 5 2002

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

HORWITZ, David A.

espond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995 Complete if Known Substitute for form 1449A/PTO 09/833,526 **Application Number** April 11, 2001 Filing Date

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

HUYNH, PHUONG N Examiner Name A-68983-1/RFT/RMS/RMK Attorney Docket Number of 4

First Named Inventor

Group Art Unit

Sheet	1_		of	4	Attorney	Jocket Number A-08	703-174 171C-12-1
					U.S. PATENT DOCU	JMENTS	
Examiner	Cite No.1	U.S. Patent Do	ocument Kind Co	Ja2	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	}	Number	(if know	wn)			Figures Appear
Purk	Al	6,228,359		B1	Horwitz	05-08-2001	
Puk	A2	6,358,506		Bl	Horwitz	03-2002	
100							
							
						 	
						 	RECEIVED
				_			
		<u> </u>		<u> </u>		 	JUN 2 8 2002
				├			JOIN B 0 7 552
	 	 		├	 		ECH CENTER 1600/2900
	4—			╁╌		 	ECH CENTEN 1000/2000
<u> </u>				\vdash			
	+-	 		\vdash			
				+-			
<u> </u>	-	 		+			
	+-	+		+			
	+	+		\top			<u> </u>

					FOREIGN PATENT DOCUMEN		Pages, Columns, Lines,	T^-
Examiner Initials*	Cite No.1	Foreign Patent Document Kind Code ² Office ³ Number ⁴ (if known)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
PUH	B1	wo	97/42324	A1	SCHERING CORP.	11-1997		╀
1011	B2	wo	99/48524	AL	UNIV. SOUTHERN CALIF.	09-1999		┼-
	B3	wo	99/25366	Al	UNIV. SOUTHERN CALIF.	05-1999		╁
	B4	wo	00/66158	A2	UNIV. SOUTHERN CALIF.	11-2000		+-
- -	B5	wo	01/16296	A2	UNIV. SOUTHERN CALIF.	03-2001		+
	1	一						╅
	\top	1					ļ	+
	+-	T^-	†				<u> </u>	—

ļ				
	Examiner Signature	Phys. 14	Date Considered	Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next charmonication to applicant.

1 Unique citation designation number. See attached Kinds of U.S. Patent Documents. Include the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Please type a plus sign (+) inside this box \rightarrow ond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, Complete if Known Substitute for form 1449B/PTO 09/833,526 Application Number April 11, 2001 INFORMATION DISCLOSURE Filing Date HORWITZ, David A. First Named Inventor STATEMENT BY APPLICANT 1644 Group Art Unit HUYNH, PHUONG N (use as many sheets as necessary) Examiner Name

	OTHER PRIOR ART - N Include name of the author (in C item (book, magazine, journal, s)	Examiner Name	A-68983-1/RFT/RMS/RMK										
	(430				Attorney Docket Number								
Sheet	2					OCUMENTS (where engropriste) title of the	$\overline{}$						
				ED DRIOD ART - NO	ON PATENT LITERATURE D	OCUMENTS State of the							
			OTH	ER PRIOR ART - 10	APITAL LETTERS), title of the artic	le (when appropriate), title of the	T ²						
Eminor	Cite		itama (h	MADE MADAZINE, IUULIUM, O	diam'r militia	ched · · · · · · · · · · · · · · · · · · ·							
Exammer Initials*	No.1		ttem (o	publ	lisher, city and/or country where publisher.	T cell stimulation towards apoptosis	Ì						
	 	DOOMS H	et al "	IL-2 and IL-15 direct th	ne outcome of inappropriate CD4+	1 cen sumanata	4						
- July	C1	and operay res	snective	ely," European Cytokin	te Network, 9(3):169 (1998)	of Suppression: an Interaction Between	1						
Por	1 1	GD 437 -4 of 5	"The R	ole of Transforming O	IOWILL THEFT	of Suppression: an Interaction Between	ᅪ—						
- 1	C2	CD8 ⁺ T and N	VK Cel	ls," J Exp Med 180:19:	37-1942 (1994)	-2 and NK Cell-Derived TGF-β:	1						
	C3	GRAY et al., "The Role of Transforming CD8* T and NK Cells," <i>J Exp Med</i> 180:1937-1942 (1994) CD8* T and NK Cells," <i>J Exp Med</i> 180:1937-1942 (1994) GRAY et al., "Generation of an Inhibitory Circuit Involving CD8* T Cells, IL-2 and NK Cell-Derived TGF-β: Contrasting Effects of Anti-CD2 and Anti-CD3", <i>J Immunol</i> , 160:2248-2254 (1998) Contrasting Effects of Anti-CD2 and Anti-CD3", <i>J Immunol</i> , 160:2248-2254 (1998) AUCHINCLOSS, Hugh Jr., et al., in <i>Fundamental Immunology</i> 4th Ed., Paul, W.E. (ed.) Lippincot-Raven:											
ļ	LC3												
	C4	TO TOT /	α cc Γ	wan it etal intuitie	41/10/1100	_	—						
- 1	1 04	Dhiladelphia	AUCHINCLOSS, Hugh Jr., et al, in June 1999 pp. 1182-1222. Philadelphia, New York; 1999 pp. 1182-1222. BETZ, M. and FOX, B.S., "Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines," J										
	105	DETZ M ar	od FOX	. B.S., "Prostaglandin	E2 inhibits production of 1n1 lylli	phokines out have							
	C5						- 1						
	C6	Immunol. 1991 Jan 1;146(1):108-13. BUCY, R.P. et al., FASEB J. 1995 9:A497 (Abstract)											
	100	BUCY, R.P. et al., PADED 5. 1775 7 a.m. over OVT3 monoclonal antibody,"											
	- -	COSIMI, A.B., et al., "Treatment of acute renal allograft rejection with OKT3 monoclonal antibody," Transplantation. 1981 Dec;32(6):535-9. CROUX, H., et al., "A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis," Nature.											
	~												
 	C8	GROUX, H	., et al.	, "A CD4+ T-cell subse	et inhibits antigen-specific 1-cen re								
1 1	100	1 1007 Oct 16	5·3X9(6	0002):/0/-42.	1:0	charge CDA(+) T cells With regulatory	1						
 	C9	IONULEIT	JONULEIT, H., et al., "Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory JONULEIT, H., et al., "Induction with allogeneic immature human dendritic cells," <i>J Exp Med.</i> 2000 Nov										
1 1		L' bet conduitive suffilliation with and Desire											
1	1	6;192(9):12	213 <u>-22</u> .		The state of the s	t rejection in primates," Proc Natl Acad							
	CIO	KIRK, A.D	., et al.,	, "CTLA4-Ig and anti-C	SD40 ligand prevent rend disease	rejection in primates," Proc Natl Acad	-+						
1 1		LScillS A	1997 A	ug 5,94(10).6702 2 11	- 1 turn and	l mechanism of action deliveri	1						
-	CI	KOIDE, J.	and EN	IGLEMAN, E.G., "Di	fferences in surface phenotype and suppressor T cell clones," <i>J Immus</i> T cells suppress rejection of renal	nol. 1990 Jan 1;144(1):32-40.	-+						
1 1	- 1	alloantigen	-specifi	c CD8+ cytotoxic and	suppressor 1 con ciercion of renal	allografts in rats," Nature. 1985 May	1						
	CI	T ANTO A ST	red E	et al., "Anti-idiotypic	I com supplied		+						
1 1	Ì	23-29;315	(6017):	:336-7.	t ritric oxide production by in viv	o allosensitized cells inhibits the	1						
-	CI	3 LANGRE	HR, J.N	M., et al., "Evidence that	at nitric oxide production by in vivisnal antation. 1992 Mar;53(3):632-	40.	-†						
1 1	- 1	developme	ent of a	llospecific CTL, Tran	splantation. 1992 Mar;53(3):632-	ts after blocking CD40 and CD28							
-	CI	4 LARSEN,	, C.P., ¢	et al., "Long-term accel	581):434-8	inst	$\neg \uparrow$						
1	1	Aless to tro	" Matu	no 1990 May 20,2010	33 <u>3 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - </u>	Thromboevie feshouses against	- 1						
	C	5 MIZUOC	Ш, Т.,	et al., "Both L314+ ar	ens but not against trinitrophenyl-r	notified self," J Exp Med. 1985 Aug	1						
1 1	1												
	1_												
	C	16 PEARCE	i, N.W.	, et al., "Specific unites	D4+ suppressor cells on the prese	cardiac allograft survival after treatment nee of alloantigen and cytokines, including							
		interleuki	in 2," <i>1</i>	ranspiantation. 1995	class II antigen matching on renal	allograft survival in miniature swine," $JExp$							
T.17		PESCOV	∕ITZ, N	A.D., et al., Effect of C									
V		Med. 198	84 Nov	1;160(5):1495-508.									

١	V <u>Med. 1984</u>	Nov 1;160(5):1495-508.			_
	Examiner	De 1 Sta	Date Considered	& 21/or	
	Signature	Pro N.		Draw line through citation if not in conformance and	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and TEACHMINER: Illuar is reference considered, whether the tenation is in control not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Please type a p	olus sign (+)	inside th	is box	>
-----------------	---------------	-----------	--------	---

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

d to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no pers Complete if Known Substitute for form 1449B/PTO 09/833,526 **Application Number** April 11, 2001 INFORMATION DISCLOSURE Filing Date HORWITZ, David A. First Named Inventor STATEMENT BY APPLICANT 00 Group Art Unit HUYNH, PHUONG N (use as many sheets as necessary) Examiner Name

	(use as many sheets as necessary)		Examiner Name	e	HUYNH, PHUUNG N 65 8							
	(use	as many sn				Attorney Docke		A-68983-1/RFT/RMS/RMK				
Sheet	3		of	4				A-68983-1/RF1/RIVIS/RIVIN				
					TOTAL NIC	ON PATENT LITER	RATURE I	OCUMENTS	т-			
			OTH	ER PR	IOR ART - NO	ADITAL I ETTERS), tit	le of the artic	cle (when appropriate), title of the	T ²			
	Cite		Includ	le name o	of the author (iii Ca	APITAL LETTERS), title of the article (when appropriate), title of the erial, symposium, catalog, etc.), date, page(s), volume-issue number(s), isher, city and/or country where published.						
Examiner Initials*	No.1		nem (t	DOOK, III	publi	isher, city and/or country	where publi	is levith transforming growth	7			
	1	ODI I et n	1 "Gen	e transfe	er for transplanta	ation. Prolongation of	allograft su	rvivai witti transforming g				
TH	C18	publisher, city and/or country where parameters of viral II10 gene prolongs murine cardiac allograft survival," J										
124	C19	ODII eta	Cactor-beta 1," Ann Surg. 1994 Oct;220(4):508-18; discussion 518-9. QIN, L., et al., "Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival," J. Communol. 1996 Mar 15;156(6):2316-23. RAJU, G.P., et al., "Prolongation of cardiac allograft survival with transforming growth factor-beta 1 in rats," RAJU, G.P., et al., "Prolongation of cardiac allograft survival with transforming growth factor-beta 1 in rats,"									
ł	1017	Immunol. 19										
	C20	RAIU. G.P.	., et al., "	Prolong	gation of cardiac	allograft survival Will	n transform					
	020	Transplanto	ation. 19	994 Aug	15;58(3):392-6).	tolerance by	persistence of antigen," Science. 1992	1			
	C21	DAMSDEL	I. F and	d FOW	LKES, B.J., M	afficiation of its	(Oleranee e)					
		Aug 21;257	1(5073):	1130-4.	·	arouth of mati	ire T cells a	nd can be reversed in the absence of	Ì			
	C22	ROCHA, B	3., et al.,	"Clonal	anergy blocks in	n vivo giowai oi maa.		nd can be reversed in the absence of				
	l	antigen," J	Exp Med	d. 1993	May 1;177(5):1	onatal and adult tolera	nce," Immu	mol Rev. 1989 Feb;107:179-202.	- }			
	C23	ROSER, B	J., "Cel	llular me	echanisms in nec	Official axid action		T 2 coventor				
	4_		CIT C	et al "I	Immunologic sel	lf-tolerance maintaine	d by activate	ed T cells expressing IL-2 receptor	- 1			
	C24	alpha chains (CD25). Breakdown of a single mechanism of seri terrains										
\ \	- 1	alpha-chair	1995 Au	ig 1:155	5(3):1151-64.			Today 2000 Feb:21(2):95-9.				
 	C25	SEDDON	B and	MASO	N, D., "The thire	d function of the thym	ius," <i>Immui</i>	not 1 oaay. 2000 1 00,5 - (
1 1	1023	Immunol. 1995 Aug 1;155(3):1151-64. SEDDON, B. and MASON, D., "The third function of the thymus," Immunol Today. 2000 Feb;21(2):95-9. SHEVACH, E.M., "Regulatory T cells in autoimmmunity," Annu Rev Immunol. 2000;18:423-49.										
	C26	SHEVACH, E.M., "Regulatory T cells in autoimminutity, Annual Control of the Contr										
1 1	1.	l l						1 and A radiation-resistant nost	- 1			
	C27	SINGER, A., et al., "Self recognition in allogeneic radiation bone marrow chimeras. A radiation-resistant host clement dictates the self specificity and immune response gene phenotype of T-helper cells," <i>J Exp Med.</i> 1981 May element dictates the self specificity and immune response gene phenotype of T-helper cells," <i>J Exp Med.</i> 1981 May										
1	- }	element di	ictates tr	ne seii s	pecificity and in			Step of human T helper	$\neg \uparrow$			
		1;153(5):	1280-30	G et a	1 "Prostaglandi	n E2 differentially mo	dulates cyto	okine secretion profiles of human T helper				
1 1	C2	3 SNIJDEW	VLN1, F.	mmuno	l. 1993 Jun 15;1	150(12):5321-9.		o				
 	- C2	CTAD7I	TF et	t al "C	thimerism and do	Onor-specific nomework	tivity 27 to 2	29 years after kidney allotransplantation,"				
1 1	102	Transpla	ntation.	1993 J	un;55(6):1272-7	7		ia the antigen-presenting cell," Eur J	l			
 	- C3	O TAAMS	L.S., et	: al., "Ar	nergic I cells act	lively suppress 2	responses vi	a the anagen pro-				
1		I I	1 1998 S	Sen: 280:	9):2902-12			1. induced tolerance to the	1			
 	- C	1 TOMITA	4, Y., et	al., "Im	portance of supp	pressor I cens in cycli	ired in mair	ide-induced tolerance to the ntaining a skin allograft tolerance?" J	1			
1	1	1 11 2	anonder	ศ สมเดสท	Heelis. 15 Hilacu	Ollina -						
1		Immuno	<i>l</i> . 1990 .	Jan 15,1	144(2):403-13.	inhibit the antigen-pre	esenting fun	ection of dendritic cells," J Immunot. 2000				
	C	Immunol. 1990 Jan 15;144(2):463-73. C32 VENDETTI, S., et al., "Anergic T cells inhibit the antigen-presenting function of dendritic cells," J Immunol. 2000 Aug 1;165(3):1175-81. C33 VERBANAC, K.M., et al., "A role for transforming growth factor-beta in the veto mechanism in transplant										
		Aug 1;10	65(3):11	1/3-81.	al "A role for t	ransforming growth f	actor-beta ii	n the veto mechanism in transplant				
	/ C	33 VERBA	MAC, K	Livi., et	ai., Alocalor	27;57(6):893-900.						
- I V	L L	1	- " Ture	enlanta	ition. 1994 Mai	21,31(0).050						

l		torer			
Ì					
١			Date	Starlox	
١	Examiner		Considered	801100	
	Signature		in Amen 600 Draw	line through citation if not in conformation	nce and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Please type a plus sign	(+) inside	this box \rightarrow
-------------------------	------------	------------------------

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ection of information unless it contains a valid OMB control number.

	(Z)	C. C	place it contains a valid OMB control r	iumber.	
ι	Inder the Paperwork Reduction Act of 1995, no pende are required to be por	nd to a collection of information u	Complete if Known		
ſ	1440D/DTO	Application Number	09/833,526	<u>유</u>	
	·	Filing Date	April 11, 2001	<u> </u>	
١	INFORMATION DISCLOSURE	First Named Inventor	HORWITZ, David A.	_ <u>=</u> _	
١	STATEMENT BY APPLICANT	Group Art Unit	1644		Ø
	(use as many sheets as necessary)	Examiner Name	HUYNH, PHUONG N		
		Attorney Docket Number	A-68983-1/RFT/RMS/RMK	<u></u>	<u> </u>
- 1	late 14	1 200 200		100	

Sheet	4		of	4 _		Attorn	ey Docket I	Nullioci	A-00705-1			2
Sheet						T D A COLON	TITEDA	TURED	OCUMENT	rs		/290
			OTH	ER PR	AIOR ART - NON	PATEN	TEDEL Sitle	of the articl	e (when appro	priate), title o	f the	
Examiner Initials*	Cite No.1		item (b	oook, ma	agazine, journai, seria	ar, symposic	or country W	here publis	shed.			
Put	C34	WEKERLE, T., et al., "Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance," <i>Transplantation</i> . 1999 Nov						ov				
	C35	15;68(9):134 WILSON, D.	8-55. B., "Idi	otypic r	regulation of T cell	ls in graft-v	n graft-versus-host disease and autoimmunity," Immunol Rev. 1989					9
	C36	Feb;107:159-	<u> 77. </u>			- daladia II	10/Fc in m	urine mod	dels of lipopo	lysaccharide	-induced	
		septic shock	and allo	Geneic	islet transplantation of T	TH1/TH2 I	Phenotype 1	Differentia	tion in Direc	tly Allorespo	onsive CD4+	
	C37	Human T Ce	:lls," T <u>r</u>	ansplan	tation, 62(8).1093	-1101 (00	2. 1.1	1 Entere	ativin B (SEI	3): A Mono	valent T Cell	
	C38	Mitogen Tha	ıt Stimu	ilates C	ytotoyuc i rympu	locytes out						
	C39	ZELLER et	al., "Inc	duction	2687 (1986) of CD4+ T Cell A	lloantigen-	-Specific H	yporespon	siveness by I	L-10 and TC	}F-β', Journ	ai
	C40	of Immunolo	"A Nev	w Type	of CD4+ Suppres	sor T cell (Completely	Prevents S	Spontaneous Autoimmunit	Autoimmun y, 9:331-339	ie Diabetes ai (1996)	nd
	C41	ROOK et al	., "Effe	cts of T	ransforming Grow	vin racioi	p on me ra	av 136/10	1)-3916-3920	(1986)		lytic
-+	C42	Activity and ASAI O, et a	al., "Su r cells a	ng of In ppressio after allo	on of graft-versus-	host diseas ow transpla	se and ampl antation,".	ification of Journal of	f graft-versus Clinical Inv	s-tumor effect estigation 1	ets by activate 01(9):1835-1	ed 1842
	C43	(1998)			-cell receptor + CI th factor-β-treated			1 1-1.	asked cell cv	cle progressi	on in interlet	ukin
 	/ C4	97:565-571	(Jan 2	001)	lular immunothera	py: NK ce	lls and bone	e marrow t	transplantatio	on," Histol I	Histopathol	
1		15:1201-1.	210 (20	000)								
		 										

Examiner Signature	DX N H	Date Considered	8/21/02	
Bigination		a	w line through citation if not in conformance	e and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.